EPIZYME INC (EPZM) Stock Price, Forecast & Analysis
USA - NASDAQ:EPZM - US29428V1044 - Common Stock
EPZM Key Statistics, Chart & Performance
The current stock price of EPZM is 1.47 USD. In the past month the price decreased by -0.68%. In the past year, price decreased by -72.78%.
EPZM Latest News, Press Relases and Analysis
EPZM Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 24.59 | 410.48B | ||
| AMGN | AMGEN INC | 15.4 | 181.29B | ||
| GILD | GILEAD SCIENCES INC | 15.26 | 155.13B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 25.18 | 112.08B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.41 | 73.50B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 880.71 | 58.88B | ||
| INSM | INSMED INC | N/A | 40.84B | ||
| NTRA | NATERA INC | N/A | 28.04B | ||
| BIIB | BIOGEN INC | 10.01 | 24.56B | ||
| UTHR | UNITED THERAPEUTICS CORP | 17.67 | 21.10B | ||
| INCY | INCYTE CORP | 16.22 | 20.34B | ||
| NBIX | NEUROCRINE BIOSCIENCES INC | 34.66 | 14.37B |
Related stock screener links
About EPZM
Company Profile
Epizyme, Inc. is a clinical-stage biopharmaceutical company. The company is headquartered in Cambridge, Massachusetts and currently employs 250 full-time employees. The company went IPO on 2013-05-31. The firm is engaged in the treatment of people with cancer through the discovery, development, and commercialization of epigenetic medicines. The firm's lead product TAZVERIK (tazemetostat) is used for epithelioid sarcoma (ES), and follicular lymphoma (FL). Tazemetostat is an oral, selective small molecule inhibitor of the EZH2 histone methyltransferase (HMT), for the treatment of adult and pediatric patients aged 16 years and older with metastatic or locally advanced ES not eligible for complete resection. The company is developing tazemetostat for lymphomas and B-cell malignancies, including B-cell lymphoma (DLBCL), mantle cell lymphoma (MCL), multiple myeloma and others. Its advanced product candidate, EZM0414, is an oral inhibitor of the SETD2 HMT. The firm is assessing the use of tazemetostat for immuno-oncology-sensitive tumors, such as small cell lung cancer, prostate cancer, and others.
Company Info
EPIZYME INC
400 Technology Sq Ste 4
Cambridge MASSACHUSETTS 02139 US
CEO: Robert B. Bazemore
Employees: 250
Phone: 16172295872.0
EPIZYME INC / EPZM FAQ
What does EPIZYME INC do?
Epizyme, Inc. is a clinical-stage biopharmaceutical company. The company is headquartered in Cambridge, Massachusetts and currently employs 250 full-time employees. The company went IPO on 2013-05-31. The firm is engaged in the treatment of people with cancer through the discovery, development, and commercialization of epigenetic medicines. The firm's lead product TAZVERIK (tazemetostat) is used for epithelioid sarcoma (ES), and follicular lymphoma (FL). Tazemetostat is an oral, selective small molecule inhibitor of the EZH2 histone methyltransferase (HMT), for the treatment of adult and pediatric patients aged 16 years and older with metastatic or locally advanced ES not eligible for complete resection. The company is developing tazemetostat for lymphomas and B-cell malignancies, including B-cell lymphoma (DLBCL), mantle cell lymphoma (MCL), multiple myeloma and others. Its advanced product candidate, EZM0414, is an oral inhibitor of the SETD2 HMT. The firm is assessing the use of tazemetostat for immuno-oncology-sensitive tumors, such as small cell lung cancer, prostate cancer, and others.
What is the stock price of EPIZYME INC today?
The current stock price of EPZM is 1.47 USD. The price decreased by -1.34% in the last trading session.
What is the dividend status of EPIZYME INC?
EPZM does not pay a dividend.
How is the ChartMill rating for EPIZYME INC?
EPZM has a ChartMill Technical rating of 5 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
What is the GICS sector and industry of EPZM stock?
EPIZYME INC (EPZM) operates in the Health Care sector and the Biotechnology industry.
Can you provide the PE ratio for EPZM stock?
EPIZYME INC (EPZM) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.68).
EPZM Technical Analysis
ChartMill assigns a technical rating of 5 / 10 to EPZM. When comparing the yearly performance of all stocks, EPZM is one of the better performing stocks in the market, outperforming 97.75% of all stocks.
EPZM Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to EPZM. EPZM may be in some trouble as it scores bad on both profitability and health.
EPZM Financial Highlights
Over the last trailing twelve months EPZM reported a non-GAAP Earnings per Share(EPS) of -1.68. The EPS increased by 33.33% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | -391.89% | ||
| ROA | -78.64% | ||
| ROE | N/A | ||
| Debt/Equity | -11.48 |
EPZM Forecast & Estimates
9 analysts have analysed EPZM and the average price target is 3.04 USD. This implies a price increase of 107% is expected in the next year compared to the current price of 1.47.
For the next year, analysts expect an EPS growth of 43.15% and a revenue growth 28.63% for EPZM